hcaix-in-6

Compounds 6B and 14g demonstrated significant inhibitory effects on the tumor-related subtype [HCA IX] with low nanomolar potency, while 6K was effective on [HCA XII]. These compounds can be considered leading molecules for developing future cancer therapeutic drugs based on new mechanisms of action.

hCAIX XII-IN-6, an orally active carbonic anhydrase (CA) inhibitor, targets human CA isoforms hCA I, II, IV, IX, and XII with inhibition constants (K i) of 6697 nM, 2950 nM, 4093 nM, 4.1 nM, and 7.7 nM, respectively. This compound is utilized in rheumatoid arthritis (RA) research.